youtube_live
Q2 2026 earnings • released • EPS miss -4.66% • Revenue miss -18.89%
See resultschevron_right
DNA:NYSE
Ginkgo Bioworks Holdings Inc
$7.97
arrow_downward
-6.24%(-0.53) 1D
$7.90
arrow_downward
-0.88% (-0.070)bedtimeAfter hours
Closed: Aug 7, 4:00:03 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DNA...
Open
$8.31
High
$8.37
Low
$7.49
Mkt. cap
496.73M
Avg. vol.
1.05M
Volume
1.65M
52-wk high
$17.58
52-wk low
$5.37
EPS
-$5.35
Beta
1.78
Shares outstanding
53.36M
No. of employees
485
Open
$8.31
High
$8.37
Low
$7.49
Mkt. cap
496.73M
Avg. vol.
1.05M
Volume
1.65M
52-wk high
$17.58
52-wk low
$5.37
EPS
-$5.35
Beta
1.78
Shares outstanding
53.36M
No. of employees
485
News stories
From sources across the web
Yahoo Finance
·
1 day ago
Ginkgo Bioworks Q2 Earnings Call Highlights
Profile
Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It raised $290 million in September and $350 million in October of that year. Ginkgo Bioworks went public on the New York Stock Exchange via a SPAC merger on September 17, 2021. Wikipedia
About Ginkgo Bioworks Holdings Inc
CEOJason Kelly
Employees485
Founded2008
HeadquartersBoston, Massachusetts, United States
SectorHealth care
Websiteginkgo.bio
AI content may include mistakes. Learn more